Leflutrozole

Leflutrozole appears to be a typographical error or a non-standard term, as there is no widely recognized medication or substance by this name in medical or scientific literature as of my last update. It's possible that the intended term might be "Letrozole," a well-known medication used in certain breast cancer treatments and fertility issues. Given this, I will proceed to create a detailed entry based on "Letrozole," assuming that was the intended subject. If "Leflutrozole" is a specific topic with information available after my last update, the following content would not apply.
Letrozole
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor used in the treatment of hormonally-responsive breast cancer after surgery. It has also been used in the treatment of endometriosis and is employed in fertility treatments for women with ovulation problems. Letrozole is taken by mouth.
Medical Uses[edit]
Letrozole is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It has shown to be effective in significantly reducing the risk of cancer recurrence. Additionally, it is used off-label for ovulation induction to treat infertility in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders.
Mechanism of Action[edit]
Letrozole works by inhibiting the enzyme aromatase, which is involved in the production of estrogens in the body. By decreasing estrogen levels, letrozole can slow or stop the growth of hormone-sensitive tumors.
Side Effects[edit]
Common side effects of letrozole include hot flashes, joint pain, fatigue, and increased risk of osteoporosis. It is contraindicated in women who are pregnant or breastfeeding due to potential harm to the fetus or infant.
Pharmacology[edit]
Letrozole is a nonsteroidal inhibitor of aromatase which effectively lowers estrogen levels in postmenopausal women, leading to a reduction in the size and growth rate of certain types of breast tumors that require estrogen to grow.
History[edit]
Letrozole was approved for medical use in the United States in 1997 and is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian